Jasper Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

JSPR$16.37-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10–K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 5, 2024	JASPER THERAPEUTICS, INC.
	By:	/s/ Ronald Martell
		Ronald Martell Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Thomas G. Wiggans
Signature	Title	Date
/s/ Ronald Martell	President, Chief Executive Officer and Director	March 5, 2024
Ronald Martell	(Principal Executive Officer)
/s/ Herb Cross	Chief Financial Officer	March 5, 2024
Herb Cross	(Principal Accounting and Financial Officer)
/s/ Thomas G. Wiggans	Chairperson of the Board	March 5, 2024
/s/ Scott Brun, M.D.	Director	March 5, 2024
Scott Brun, M.D.
/s/ Anna French, D.Phil.	Director	March 5, 2024
Anna French, D.Phil.
/s/ Vishal Kapoor	Director	March 5, 2024
Vishal Kapoor
/s/ Christian W. Nolet	Director	March 5, 2024
Christian W. Nolet
/s/ Judith Shizuru, M.D., Ph.D.	Director	March 5, 2024
Judith Shizuru, M.D., Ph.D.
/s/ Kurt von Emster	Director	March 5, 2024
Kurt von Emster

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.